The study design for the TRuE-V long-term extension study is discussed.
In this segment, the discussion between Gary Owens, M.D., and David Rosmarin, M.D., revolves around the design and findings of the TRuE-V long-term extension study for vitiligo. The study segregates patients into two cohorts based on their treatment response. Cohort A consists of highly responsive individuals, randomly assigned either to continue medication or switch to the vehicle arm. Cohort B focuses on patients with less optimal results, exploring the possibility of additional benefits with continued use of ruxolitinib and calcineurin inhibitors. The experts emphasize the study’s significance in addressing questions related to the necessity of indefinite
medication for patients showing a response and the potential for delayed response in those initially less responsive. The discussion highlights the importance of both study arms in understanding vitiligo treatment outcomes and generating valuable insights for the future management of the disease.
Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.